COVID-19: an unexpected indication for anti-rheumatic therapies?
- PMID: 32374874
- PMCID: PMC7239095
- DOI: 10.1093/rheumatology/keaa194
COVID-19: an unexpected indication for anti-rheumatic therapies?
Figures
Comment in
-
Why not to use colchicine in COVID-19? An oldanti-inflammatory drug for a novel auto-inflammatory disease.Rheumatology (Oxford). 2020 Jul 1;59(7):1769-1770. doi: 10.1093/rheumatology/keaa217. Rheumatology (Oxford). 2020. PMID: 32472681 Free PMC article. No abstract available.
References
-
- Gorbalenya AE. Severe acute respiratory syndrome-related coronavirus: The species and its viruses – a statement of the Coronavirus Study Group. bioRxiv 2020, doi: 10.1101/2020.02.07.937862.
-
- World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report – 69. 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/2...(29 March 2020, date last accessed).
-
- Wu Z, McGoogan JM.. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020. (in press), doi: 10.1001/jama.2020.2648. - PubMed
-
- Wan S, Yi Q, Fan S, Lv J, Zhang X, Guo L. et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). medRxiv 2020, doi: 10.1101/2020.02.10.20021832.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
